Hostname: page-component-7b9c58cd5d-sk4tg Total loading time: 0 Render date: 2025-03-15T22:46:57.290Z Has data issue: false hasContentIssue false

Complete atrio-ventricular heart block, a not to be forgotten complication in transcatheter closure of perimembranous ventricular septal defect – a case report and review of literature

Published online by Cambridge University Press:  31 May 2021

Ming Chern Leong*
Affiliation:
Paediatric & Congenital Heart Centre, Institut Jantung Negara, Kuala Lumpur, Malaysia
Mazeni Alwi
Affiliation:
Paediatric & Congenital Heart Centre, Institut Jantung Negara, Kuala Lumpur, Malaysia
*
Author for correspondence: Ming Chern Leong, Paediatric & Congenital Heart Centre, Institut Jantung Negara, 145, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia. Tel: +603 2617 8470; Fax: +603 2694 6478. E-mail: mcleong@ijn.commy
Rights & Permissions [Opens in a new window]

Abstract

Device occlusion of perimembranous ventricular septal defect is gaining popularity with the emergence of newer, softer occluders and improved technical know-how. We report a 26-year-old lady with a moderate size perimembranous ventricular septal defect who had a new onset of bundle branch block shortly after device closure. The patient subsequently developed a complete atrio-ventricular heart block.

Type
Brief Report
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Device closure of perimembranous ventricular septal defect is increasingly popular in small and moderate size perimembranous ventricular septal defect. It offers a less invasive treatment of perimembranous ventricular septal defect without the need for cardiopulmonary bypass surgery. Nevertheless, complete atrio-ventricular block as a serious complication has made device closure of this defect a contentious procedure especially in the western world.

Case report

A 26-year-old woman with a moderate size perimembranous ventricular septal defect underwent transcatheter closure. Clinically, she was asymptomatic but since there was volume loading to the left heart chambers, the ventricular septal defect occlusion was undertaken. The procedure was performed under general anaesthesia. A pre-procedural echocardiogram showed a moderate size perimembranous ventricular septal defect with an aneurysmal pouch. The pouch has a diameter of 15 mm and a solitary exit, measuring 6.2 mm (Fig 1). The aortic cusp did not prolapse into the defect. Qp:Qs = 1.6:1, while the pulmonary vascular resistance was 1.2 Woods unit. A Konar-MF ventricular septal defect Occluder size 10–8 (Lifetech Scientific, Shenzhen, China), which has a 10 mm body diameter at the left ventricular end and an 8 mm body diameter at the right ventricular end, was implanted retrogradely via a 6 F delivery sheath. The procedure was smooth and intra-procedure, no rhythm disturbance was noted. However, post procedure there was a new onset of partial right bundle branch block (Fig 2). The patient was discharged well the next day. However, 1 week later, the patient complained of being unwell, having bouts of vomiting which finally culminated in a syncope episode. Electrocardiogram captured during the episode revealed a complete atrio-ventricular block (Figure). The device was removed and the ventricular septal defect was patched surgically. At the time of writing, there has not been any recurrence of complete atrio-ventricular block.

Figure 1. Transoesophageal echocardiogram and angiographic profiling of the VSD before and after device occlusion. ( a ) Perimembranous inlet VSD with an aneurysmal sac which has a diameter of 15 mm and a much smaller exit of 6.2 mm; ( b ) the 10–8 device that has a body of 10 mm at the LV end and a retention disk of 2.5 mm on the sides was placed within the sac; ( c ) ventriculogram profiling of the VSD and aneurysmal sac, and ( d ) the device was away from the aortic valve, while the body of the device was not significant squeezed.

Figure 2. Change of ECG over time (a) Normal sinus rhythm prior to the procedure. The QRS axis showed left superior axis (QRS −15°) inconsistent with a perimembranous VSD with inlet extension, which is away from the aortic valve. Device closure of this VSD has a higher risk of CAVB but a lower risk of impingement onto the aortic cusp; (b) Partial right bundle branch block shortly after the procedure; and (c) Complete atrio-ventricular block 1 week after the procedure.

Discussion

Transcatheter closure of the perimembranous ventricular septal defect is commonly performed outside of western countries due to its proximity to the conduction bundle and its association with complete atrio-ventricular block during device closure. However, being overwhelmingly the commonest ventricular septal defect has driven the quest to find a suitable device to close this defect. The first being the Amplatzer membranous ventricular septal defect occluder. The device has been discontinued due to its high risk of complete atrio-ventricular block. The emergence of the newer devices, which are made up of softer nitinol mesh and hence less radial tension onto the adjacent septal wall tissue and its underlying conduction bundle, and the improved technical know-how has led to a lower procedural risk and an exponential increase in the number of device perimembranous ventricular septal defect closures. Currently, the Amplatzer Ductal Occluder I, Amplatzer Occlude II, Amplatzer Vascular Plug, the Nit-Occlude Le Coil, the Konar device, and the Occlutech Ventricular Septal Defect Occluder were the more popularly used devices. Sans the ductal occluder I, these devices have softer device architecture that better conforms to the morphology of the ventricular septal defect, causing a lesser impingement to the adjacent septal wall tissue. Despite these qualities, the incidence of a complete atrio-ventricular block is not eliminated.

Table 1 summarises the available data on the occurrence of complete atrio-ventricular block in these newer perimembranous ventricular septal defect occluders. Among these devices, only Amplatzer Ductal Occluder II and the Amplatzer Vascular Plug II have yet to have any history of complete heart block. However, the follow-up durations in most of these studies are short and hence may not be sufficient to draw a concrete conclusion. Complete atrio-ventricular block has been reported to appear as late as 9 years after closure. Reference Bai, Xu and Li12 In our patient, complete atrio-ventricular block occurred early after the procedure, and one may argue that the use of corticosteroids to reduce inflammation at the closure site may revert the heart rhythm back to normal sinus rhythm. However, a previous literature reported a 50% recurrence of complete atrio-ventricular block after a temporary resumption of normal sinus rhythm. Reference Bai, Xu and Li12 The timing of recurrence of complete atrio-ventricular block is unpredictable that brings the fear of out-of-hospital sudden cardiac death.

Table 1. Incidence of complete heart block in the “newer” ventricular septal defect occluders

ADO I = Amplatzer Ductal Occluder I; ADO II = Amplatzer Ductal Occluder II; CAVB = complete atrio-ventricular block; PMVSD = permemberanous ventricular septal defect

The appearance of an electrocardiogram change, even subtle, should raise the suspicion of an impending complete atrio-ventricular block. The progression to a complete atrio-ventricular block is unpredictable. It may occur early or late and even recur late after its initial presentation. Once a complete atrio-ventricular block occurs, early surgical removal of the device is recommended before established fibrosis takes place, precluding the recovery to rhythm normalcy. A late complete atrio-ventricular block would signal the need for a pacemaker. The possibility of a complete atrio-ventricular block should be explained to the patient prior to the procedure.

Conclusion

Complete atrio-ventricular block remains a concerning complication even in the presence of the newer occluders. The appearance of a new electrocardiogram changes should raise the suspicion of its possibility.

Acknowledgements

The authors would like to thank the Research Department of Institut Jantung Negara for its assistance in the preparation of the manuscript.

Financial Support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of Interest

None.

References

Mijangos-Vázquez, R, El-Sisi, A, Sandoval Jones, JP, et al. Transcatheter closure of perimembranous ventricular septal defects using different generations of Amplatzer devices: multicenter experience. J Interv Cardiol 2020; 2020: 8948249.10.1155/2020/8948249CrossRefGoogle ScholarPubMed
Haddad, RN, Daou, L, Saliba, Z. Device closure of perimembranous ventricular septal defect: choosing between Amplatzer occluders. Front Pediatr 2019; 7: 300.10.3389/fped.2019.00300CrossRefGoogle ScholarPubMed
Nguyen, HL, Phan, QT, Dinh, LH, et al. Nit-Occlud Lê VSD coil versus Duct occluders for percutaneous perimembranous ventricular septal defect closure. Congenital Heart Dis 2018; 13: 584593.CrossRefGoogle ScholarPubMed
El-Sisi, A, Sobhy, R, Jaccoub, V, Hamza, H. Perimembranous ventricular septal defect device closure: choosing between Amplatzer duct occluder I and II. Pediatr Cardiol 2017; 38: 596602.CrossRefGoogle ScholarPubMed
Ghaderian, M, Sabri, MR, Ahmadi, AR, Dehghan, B, Mahdavi, C, Ataei, ZZ. The efficacy and safety of using Amplatzer for transcatheter closure of atrial septal defect in small children with less than 10 kg. ARYA Atheroscler 2019; 15: 2732.Google ScholarPubMed
Zhao, LJ, Han, B, Zhang, JJ, Yi, YC, Jiang, DD, Lyu, JL. Transcatheter closure of congenital perimembranous ventricular septal defect using the Amplatzer duct occluder 2. Cardiol Young 2018; 28: 447453.10.1017/S1047951117002396CrossRefGoogle ScholarPubMed
Polat, TB, Türkmen, E. Transcatheter closure of ventricular septal defects using the Amplatzer duct occluder II device: a single-center experience. Postepy Kardiol Interwencyjnej 2016; 12: 340347.Google ScholarPubMed
Haas, NA, Kock, L, Bertram, H, et al. Interventional VSD-closure with the Nit-Occlud® Lê VSD-coil in 110 patients: early and midterm results of the EUREVECO-registry. Pediatr Cardiol 2017; 38: 215227.CrossRefGoogle ScholarPubMed
Tanidir, IC, Baspinar, O, Saygi, M, Kervancioglu, M, Guzeltas, A, Odemis, E. Use of Lifetech™ Konar-MF, a device for both perimembranous and muscular ventricular septal defects: a multicentre study. Int J Cardiol 2020; 310: 4350.CrossRefGoogle ScholarPubMed
Haddad, RN, Daou, LS, Saliba, ZS. Percutaneous closure of restrictive-type perimembranous ventricular septal defect using the new KONAR multifunctional occluder: midterm outcomes of the first middle-eastern experience. Catheter Cardiovasc Interv 2020; 96: E295E302.10.1002/ccd.28678CrossRefGoogle ScholarPubMed
Hua, N, Aquino, P, Owada, CY. Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer vascular plug-II. Cardiol Young 2016; 26: 11941201.CrossRefGoogle ScholarPubMed
Bai, Y, Xu, XD, Li, CY, et al. Complete atrioventricular block after percutaneous device closure of perimembranous ventricular septal defect: a single-center experience on 1046 cases. Heart Rhythm 2015; 12: 21322140.CrossRefGoogle ScholarPubMed
Figure 0

Figure 1. Transoesophageal echocardiogram and angiographic profiling of the VSD before and after device occlusion. (a) Perimembranous inlet VSD with an aneurysmal sac which has a diameter of 15 mm and a much smaller exit of 6.2 mm; (b) the 10–8 device that has a body of 10 mm at the LV end and a retention disk of 2.5 mm on the sides was placed within the sac; (c) ventriculogram profiling of the VSD and aneurysmal sac, and (d) the device was away from the aortic valve, while the body of the device was not significant squeezed.

Figure 1

Figure 2. Change of ECG over time (a) Normal sinus rhythm prior to the procedure. The QRS axis showed left superior axis (QRS −15°) inconsistent with a perimembranous VSD with inlet extension, which is away from the aortic valve. Device closure of this VSD has a higher risk of CAVB but a lower risk of impingement onto the aortic cusp; (b) Partial right bundle branch block shortly after the procedure; and (c) Complete atrio-ventricular block 1 week after the procedure.

Figure 2

Table 1. Incidence of complete heart block in the “newer” ventricular septal defect occluders